Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
J Nerv Ment Dis. 2020 Jul;208(7):566-573. doi: 10.1097/NMD.0000000000001171.
This study examined opinions of American psychiatrists regarding prior authorization (PA) requirements for third-party payer coverage of medications and quantified perceived impact of these requirements on clinical practice. One thousand selected psychiatrist members of the American Psychiatric Association were invited to participate in a survey. Response rate was 33.1%. Respondents predominantly believed the obligation to obtain PA reduces job satisfaction and negatively impacts patient care. A total of 59.9% of respondents reported employing either diagnosis modification or falsification of previous medication trials at least occasionally in order to obtain PA. A total of 66.6% refrained at least occasionally from prescribing preferred medications due to PA requirement or expectation of one. On multivariate analysis, risk factors for refraining at higher frequency included seeing 300 or more patients in the previous 3 months, engaging more frequently in diagnosis modification, and reporting increased perception that obtaining PA reduces time for patient care.
这项研究调查了美国精神科医生对第三方支付者覆盖药物的事先授权 (PA) 要求的看法,并量化了这些要求对临床实践的影响。邀请了 1000 名美国精神病学协会的选定精神科医生成员参加调查。回复率为 33.1%。受访者普遍认为获得 PA 的义务降低了工作满意度,并对患者护理产生负面影响。共有 59.9%的受访者报告说,他们至少偶尔会采用修改诊断或伪造以前的药物试验来获得 PA。共有 66.6%的受访者至少偶尔会因为 PA 的要求或预期而避免开首选药物。在多变量分析中,更频繁地避免开处方的风险因素包括在前 3 个月内看诊 300 名或更多患者、更频繁地进行诊断修改,以及报告认为获得 PA 会减少与患者护理的时间。